Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
BACKGROUND: RTS,S/AS01(E) is the lead candidate pre-erythrocytic malaria vaccine. In Phase IIb field trials the safety profile was acceptable and the efficacy was 53% (95%CI 31%-72%) for protecting children against clinical malaria caused by P. falciparum. We studied CS-specific T cell responses in...
Main Authors: | Olotu, A, Moris, P, Mwacharo, J, Vekemans, J, Kimani, D, Janssens, M, Kai, O, Jongert, E, Lievens, M, Leach, A, Villafana, T, Savarese, B, Marsh, K, Cohen, J, Bejon, P |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
2011
|
Títulos similares
-
Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
por: Ally Olotu, et al.
Publicado: (2011-01-01) -
A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E
por: Ndungu, F, et al.
Publicado: (2012) -
Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children
por: Olotu, A, et al.
Publicado: (2014) -
Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.
por: Ally Olotu, et al.
Publicado: (2014-01-01) -
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
por: Olotu, A, et al.
Publicado: (2011)